Adma Biologics reported $80.75M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Adma Biologics USD 80.75M 8.07M Mar/2026
Alnylam Pharmaceuticals USD 825M 4.3M Mar/2026
BioCryst Pharmaceuticals USD 153.05M 4.16M Dec/2025
Minerva Neurosciences -4.27M 26.79M Dec/2024
Novavax USD 125.04M 76.09M Dec/2025
Omeros USD -33.16M 18.52M Jun/2024
Takeda JPY 688.84B 101.71B Mar/2026